<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679678</url>
  </required_header>
  <id_info>
    <org_study_id>MWPH-2012-08-01</org_study_id>
    <nct_id>NCT01679678</nct_id>
  </id_info>
  <brief_title>A Study, Performed in Subjects With Post Traumatic-post Surgical ,Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily Regimen</brief_title>
  <official_title>A Double Blind, Randomized, Controlled Study, Performed in Subjects With Post Traumatic-post Surgical, Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of Polyheal-2 vs PolyHeal in Once Daily Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind , randomized, controlled, two-arm study aiming to evaluate the safety&#xD;
      and efficacy of Polyheal-2 vs PolyHeal, in once daily application as compared to historical&#xD;
      control. The study will enroll adult subjects with post traumatic/post surgical, venus&#xD;
      insufficiency and diabetic hard to heal wounds who meet the entrance criteria which will be&#xD;
      followed for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo screenibg period of up to two weeks. Following to eligibilidy&#xD;
      confirmation subjects will be randomized into one of the two treatment groups and treated&#xD;
      with study device once daily for 4 weeks.&#xD;
&#xD;
      Continuation of study device for additional period is based on wound healing progression and&#xD;
      under investigator's discretion.&#xD;
&#xD;
      Subjects will be followed up weekly following to 4 weeks of active treatment for additional 8&#xD;
      weeks untol week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business considerations&#xD;
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of at least (â‰¥)75% viable granulation tissue (grade 7 or 8 on the granulometer scale) after 4 weeks of study treatment (active phase)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Surgical Wound Dehiscence</condition>
  <arm_group>
    <arm_group_label>PolyHeal 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Negatively charged 5-micron polystyrene microspheres in Water For Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PolyHeal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PolyHeal 2</intervention_name>
    <description>PolyHeal is a sterile medical device</description>
    <arm_group_label>PolyHeal 2</arm_group_label>
    <other_name>PolyHeal</other_name>
    <other_name>PolyHeal is a sterile medical device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polyheal</intervention_name>
    <description>PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in</description>
    <arm_group_label>PolyHeal</arm_group_label>
    <other_name>PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in DMEM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hard to heal/chronic post traumatic post surgical ,venus insufficiency and diabetic&#xD;
             wound refractory to healing at least 4 weeks prior to study treatment (one or more&#xD;
             target wound/s will be eligible per each subject to be treated by the same agent)&#xD;
&#xD;
          -  Subjects who are able to read, understand, and sign the informed consent form. In case&#xD;
             of compromised mental capacity, approval and signature of a legal guardian is&#xD;
             required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a systemic infection or significant local infection with copious purulent&#xD;
             drainage, fluids drainage, gangrene, or cellulites, or necrosis at the target wound&#xD;
             site, as well as nonviable tissue, sinus tracts or tunnels that cannot be removed by&#xD;
             debridement.&#xD;
&#xD;
          -  Wounds with exposed bones, tendons or ligaments&#xD;
&#xD;
          -  Wounds with exposed orthopedic implants&#xD;
&#xD;
          -  Wounds with exposed breast prostheses&#xD;
&#xD;
          -  Uncontrolled diabetes with HbA1c &gt;11%&#xD;
&#xD;
          -  Subjects with BMI greater than 35kg/m2&#xD;
&#xD;
          -  Woman who are pregnant or nursing, or of childbearing potential and are not using&#xD;
             adequate contraception&#xD;
&#xD;
          -  Participation in another clinical drug/device trial within 30 days prior to the&#xD;
             Screening visit or during this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Berezovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Department of Plastic and reconstructive surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eyal Gur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Plastic and Reconstructive Surgery Department, Souraski Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonid Kogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Plastic Surgery Department Western Galilee Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yehuda Ulman, Proffesor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Plastic surgery department ,Rambam Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital</name>
      <address>
        <city>Naharia</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 20, 2012</study_first_submitted>
  <study_first_submitted_qc>September 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2012</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Dehiscence</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

